The U.S. Food and Drug Administration approved FILSPARI, developed by Travere Therapeutics, as the first medicine for focal segmental glomerulosclerosis (FSGS). Travere announced the approval on April 13, 2026. Company executives held a business update conference call that evening to discuss the milestone.
Travere Therapeutics announced the FDA's approval of FILSPARI for FSGS patients earlier on April 13, 2026. The drug marks the first approved treatment for this kidney condition, according to the company. A press release and presentation slides are available on Travere's corporate website. The conference call featured President and CEO Eric Dube leading the discussion, joined by Chief Medical Officer Jula Inrig and Chief Commercial Officer Peter Heerma for prepared remarks. Chief Research Officer William Rote and Chief Financial Officer Chris Cline participated in the question-and-answer session. Analysts from firms including Leerink Partners, JPMorgan Chase, Guggenheim Securities, Wedbush Securities, TD Cowen, Cantor Fitzgerald, Wells Fargo Securities, Jefferies, Citigroup, BofA Securities, and Stifel joined the call. Nivi Nehra, Vice President of Corporate Communications and Investor Relations, opened the proceedings.
